Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study DOI Creative Commons
Xin Liu,

Kaihua Zhao,

Ziyan Zhang

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 151(1)

Published: Dec. 27, 2024

The objective of the current research was to assess clinicopathological characteristics and long-term prognosis triple-negative breast cancer (TNBC) patients with human epidermal growth factor receptor 2 (HER2)-low status following surgery. A total 202 TNBC treated at Qingdao Central Hospital from January 2010 December 2019 were included, comprising 71 HER2-low 131 HER2-zero patients. Propensity score matching (PSM) applied minimize differences between cohorts. had lower histological grade, Ki-67 expression levels, a higher prevalence hypertension compared Before after PSM, group consistently exhibited recurrence rate longer RFS validated as an independent low-risk for both pre-PSM (HR 0.354, 95% CI 0.178–0.706, p = 0.003) post-PSM 0.405, 0.185–0.886, 0.024). No statistically significant in mortality OS observed, before PSM. show differences. Compared HER2-zero, is linked better serves

Language: Английский

Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review DOI Open Access
Javier Muñoz, Sabrina Nucera,

Natalia García

et al.

The Breast, Journal Year: 2025, Volume and Issue: unknown, P. 104465 - 104465

Published: April 1, 2025

We present the first documented oncologic case of a type I Kounis syndrome (KS) following paclitaxel administration, in very young patient with HER2-positive(+) early-stage breast cancer (BC). KS is relatively rare acute coronary triggered by anaphylactic or hypersensitivity reactions, which there limited awareness among healthcare providers. It subdivided four subtypes depending on cardiac artery medical history. While no established management guidelines exist, its treatment requires addressing severe infusion reactions while ensuring proper myocardial perfusion. hereby illustrate successful and report how tumor genomics through novel HER2DX assay helped re-defining entire neo/adjuvant strategy. integrates size nodal involvement 27 genes' expression data tracking biological BC-related immunologic signatures so to estimate prognostic predictive score. This demonstrates clinical genomic can be effectively integrated optimize therapeutic decisions HER2+ BC, offering model for personalized care also atypical complex cases.

Language: Английский

Citations

1
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer DOI Creative Commons
Francesco Schettini,

S. Nucera,

F. Brasó-Maristany

et al.

ESMO Open, Journal Year: 2024, Volume and Issue: 9(7), P. 103619 - 103619

Published: June 28, 2024

The characterization and comparison of gene expression intrinsic subtype (IS) changes induced by neoadjuvant chemotherapy (NACT) endocrine therapy in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low versus HR+/HER2-0 breast cancer (BC) has not been conducted so far. Most evidence on the association HER2 status with pathologic responses prognosis HR+/HER2-negative BC is controversial restricted to NACT-treated disease. Similarly, a temporal heterogeneity described only NACT.

Language: Английский

Citations

8
Hormone receptor-positive early breast cancer in young women: A comprehensive review DOI
Benjamín Walbaum, Isabel García-Fructuoso, Olga Martínez‐Sáez

et al.

Cancer Treatment Reviews, Journal Year: 2024, Volume and Issue: 129, P. 102804 - 102804

Published: July 14, 2024

Language: Английский

Citations

4
From Text to Insight: A Natural Language Processing-Based Analysis of Burst and Research Trends in HER2-low Breast Cancer Patients DOI Creative Commons

Muyao Li,

Ang Zheng, Mingjie Song

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: 106, P. 102692 - 102692

Published: Feb. 22, 2025

With the intensification of population aging, proportion elderly breast cancer patients is continuously increasing, among which those with low HER2 expression account for approximately 45 %-55 % all cases within traditional HER2-negative cancer. Concurrently, significant therapeutic effect T-DXd on HER2-low tumors has brought this group into public spotlight. Since clinical approval in 2019, there been a vertical surge volume publications domain. We analyzed 512 articles from Web Science Core Collection using bibliometrics, topic modeling, and knowledge graph techniques to summarize current state trends research Research efforts are particularly concentrated United States China. Our analysis revealed six main directions: detection, omics biomarkers, basic translational research, neoadjuvant therapy prognosis, progress ADC drugs trials. To enhance efficacy safety antibodydrug conjugates (ADCs), researchers actively exploring potential drug candidates other than T-DXd, numerous emerging practice By incorporating treatment strategies such as immunotherapy employing circulating tumor cell (CTC) detection techniques, made toward improving prognosis expression. believe that these hold promise compelling evidence may constitute distinct independent subtype.

Language: Английский

Citations

0
Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue DOI Creative Commons

Xiaoshuan Liang,

Yiwei Qin,

Pengwei Li

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17

Published: Jan. 1, 2025

Currently, female breast cancer (BC) represents the highest incidence of globally. This trend has raised significant attention regarding young women (BCYW). With advancements in treatment technology, BCYW survivors are living longer; however, risk developing or succumbing to a second primary (SPC) greatly increased. In addition, several factors, including age, menstrual cycle, hormonal changes, obesity, pregnancy, and breastfeeding, interact influence development SPC make its more difficult. study investigates relationship between SPC, focusing on morbidity trends, pathological genomics, recurrence rates, survival times, modalities, physiological fertility. Most involve BRCA pathogenic variants fall under triple-negative human epidermal growth factor receptor 2-overexpressing subtypes, increasing SPC. While there regional variations time following diagnosis an long-term outcomes remain unfavorable. choice for prolonged cumulative toxic effect. The combination endocrine therapy chemotherapy is effective treating BC, but it simultaneously increases specifically endometrial cancer. Furthermore, radiotherapy associated with heightened contralateral BC lung We aim address existing gaps literature enhance awareness risks BCYW, thereby offering valuable insights clinical treatment.

Language: Английский

Citations

0
Clinical Impact and Genomic Features of Human Epidermal Growth Factor Receptor 2–Low Tumors in BRCA1/2 -Mutated Triple-Negative Breast Cancer DOI
Furong Kou,

Huimin Liu,

Yaxin Zhang

et al.

JCO Precision Oncology, Journal Year: 2025, Volume and Issue: 9

Published: March 1, 2025

PURPOSE Data about the clinical impact of human epidermal growth factor receptor 2 (HER2)–low expression in BRCA1/2 -mutated breast cancer (BC) are limited. This study aimed to clarify relevance HER2-low operable BC. MATERIALS AND METHODS A total 495 HER2-negative BC with germline pathogenic variants treated at our institute between October 2003 and September 2020 were included. was defined as immunohistochemistry (IHC) 1+ or 2+/fluorescence situ hybridization–negative, while HER2-zero IHC 0. Tumor DNA from 25 triple-negative BCs (TNBCs) subjected whole-exome sequencing. RESULTS Among 186 BRCA1 carriers, 38.8% TNBC (n = 121) 52.3% hormone receptor–positive/HER2-negative 65) exhibited tumors subgroup; among 309 BRCA2 44.9% 49) 68.1% 260) subgroup. After a median follow-up 10.9 years (range, 1.23-19.8 years), TNBC, significantly associated better recurrence-free survival (RFS; 10-year RFS: 90.3% v 75.1%; P .015), distant (DRFS; DRFS: 92.4% 76.5%; .010), overall (OS; OS: 94.6% 77.4%; .007) than tumors. However, not observed either BRCA1- Notably, mutated showed higher homologous recombination deficiency scores those CONCLUSION patients have favorable survival, highlighting possibility stratifying these into two subgroups on basis status.

Language: Английский

Citations

0
Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study DOI Creative Commons
Jie Lian,

Ru Yao,

Siyuan Pang

et al.

Clinical Breast Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis DOI Creative Commons
Francesco Schettini, Sabrina Nucera, Tomás Pascual

et al.

Cancer Treatment Reviews, Journal Year: 2024, Volume and Issue: 132, P. 102865 - 102865

Published: Dec. 19, 2024

Language: Английский

Citations

1
Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study DOI Creative Commons
Xin Liu,

Kaihua Zhao,

Ziyan Zhang

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 151(1)

Published: Dec. 27, 2024

The objective of the current research was to assess clinicopathological characteristics and long-term prognosis triple-negative breast cancer (TNBC) patients with human epidermal growth factor receptor 2 (HER2)-low status following surgery. A total 202 TNBC treated at Qingdao Central Hospital from January 2010 December 2019 were included, comprising 71 HER2-low 131 HER2-zero patients. Propensity score matching (PSM) applied minimize differences between cohorts. had lower histological grade, Ki-67 expression levels, a higher prevalence hypertension compared Before after PSM, group consistently exhibited recurrence rate longer RFS validated as an independent low-risk for both pre-PSM (HR 0.354, 95% CI 0.178–0.706, p = 0.003) post-PSM 0.405, 0.185–0.886, 0.024). No statistically significant in mortality OS observed, before PSM. show differences. Compared HER2-zero, is linked better serves

Language: Английский

Citations

1